Clinical trial Recruiting at 1 site Interventional Ages 65 and up

Zinc supplementation in older medical patients to see if days alive and out of hospital improve

Official title: Effect of Zinc Supplementation on Occurrence of Infections in Older Medical Patients (ZOOM) - a Cluster Randomized Controlled Trial (ZOOM OUT).

Run by Herlev Hospital · NCT07367412 · Data updated 2026-11-12

Giving 22 mg of zinc once daily for 12 months to older medical patients in the ED is being tested to see if it helps more days alive and out of the hospital compared with not giving zinc.

More Older Adults (65 Years and Older) trials

Quick facts

Study typeInterventional
Ages65 Years and up
SexAll
Enrollment8000 (estimated)
SponsorHerlev Hospital
Academic / other
Locations2 sites (Herlev, Copenhagen and 1 other locations)
StatusRecruiting
StartedFebruary 1, 2026
Main results expectedMarch 15, 2028
Study endsMarch 15, 2028
Registry record updatedMay 29, 2026
Trial IDNCT07367412 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are medical patients aged 65 and older assessed in the Emergency Department at Herlev Hospital who are not taking more than 10 mg/day zinc and do not have exclusion criteria such as terminal illness, dialysis, severe dementia, or inability to understand Danish.

Probably not a fit

Patients with very advanced illness, high frailty, or conditions requiring parenteral nutrition or dialysis may not benefit or could be unsuitable.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study tests whether daily zinc sulfate for 12 months can increase the days a patient is alive and out of the hospital among older adults seen in the emergency department for acute medical issues. Participants are 65 years and older and are assigned to receive zinc or not, with follow-up over a year. The trial will monitor outcomes such as antibiotic use, readmissions, and mortality, along with overall survival and hospital-free days. It is conducted at Herlev Hospital in Denmark, with support from national and foundation partners.

Why it matters

Potential benefit: If successful, zinc supplementation could extend hospital-free days and reduce infections and related healthcare utilization in older adults.

How similar studies have gone: Prior research suggests micronutrient supplementation can influence infection and recovery in older adults, but this specific 12-month zinc strategy in acutely admitted medical patients is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* All medical patients aged ≥ 65 years assessed at the Medical Emergency Department, Herlev Hospital

Exclusion Criteria:

* Self-supplementing with zinc at time of assessment (\> 10 mg zinc/day)
* Terminal illness (life expectancy \< 6 months, estimated by Clinical Frailty Scale ≥8)
* Patients receiving parenteral nutrition (partial or complete)
* Patients treated with hemodialysis or peritoneal dialysis
* Patients know with known severe dementia
* Patients who do not understand Danish and patients with temporary civil person registration numbers (CPR)

Where it's running

  • Department of Medicine
    Herlev, Copenhagen, Denmark
    Recruiting
  • Department of Medicine, Copenhagen University Hospital - Herlev and Gentofte
    Herlev, Denmark
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.